Pay in 4 interest-free payments of $5.43 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
event-driven endpoint Obstructive Sleep Apnea Status: Phase 3 Planned Focus: OSA severity reduction (apnea-hypopnea index) with CagriSema-induced weight loss Population: Adults with moderate-severe OSA and obesity Timeline: Expected enrollment 2024-2025 NASH/MAFLD Status: Phase 2 Ongoing Focus: Hepatic steatosis, inflammation, and fibrosis improvement Population: Adults with biopsy-confirmed NASH/MAFLD Timeline: Results expected 2025 Heart Failure with Preserved EF Status: Preclinical Planning Focus: HFpEF outcomes in obese patients following substantial weight loss Rationale: Obesity-HFpEF phenotype may benefit from profound weight reduction Timeline: Early development phase Pediatric Obesity Status: Phase 2 Planning Focus: Safety, tolerability, and efficacy in adolescents (12-18 years) Population: Adolescents with obesity (BMI 95th percentile) Timeline: Expected initiation 2025 Oral Formulation Development Status: Preclinical Focus: Oral bioavailability enhancement for cagrilintide using absorption enhancers Rationale: Oral delivery could improve accessibility and adherence Timeline: Research phase
11 CDC (Subcut Injection PDF)Technique diagram and site guidance for subcutaneous injections
Injecting air bubbles
Product Specifications Lyophilized Peptides: These peptides are freeze-dried, a process that not only extends shelf life but also preserves the purity and integrity of the peptides during storage
US$ 22.53
US$ 20.99
US$ 26.84
US$ 27.89
US$ 21.70
US$ 24.21
US$ 27.50
US$ 29.34
US$ 20.61
